deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02951533

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (POLARIS)

Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment

Sponsor: Janssen-Cilag G.m.b.H

Conditions Psoriasis
Interventions Fumaric Acid Esters Guselkumab
Updated 16 times since 2017 Last updated: Feb 27, 2020 Started: Dec 12, 2016 Primary completion: Sep 13, 2017 Completion: Feb 6, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Psoriasis, this trial is completed. The trial is conducted by Janssen-Cilag G.m.b.H and has accumulated 16 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Mar 2020 · 11 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Mar 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Apr 2019 — Mar 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Apr 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen-Cilag G.m.b.H
Data source: Janssen-Cilag G.m.b.H

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Berlin, Germany , Bielefeld, Germany , Dresden, Germany , Dülmen, Germany , Düsseldorf, Germany , Erlangen, Germany , Essen, Germany , Frankfurt, Germany , Gera, Germany and 18 more locations